Drug intelligence / Profile preview

APB-R6

Development stage: Unknown
Lead developer: Aprilbio
Administration: Parenteral

Overview

APB-R6 is an investigational drug being developed by Aprilbio for the treatment of endocrine disorders. It is a new molecular entity and, based on available data, acts as an inhibitor of the thyroid stimulating hormone receptor (TSHR). The drug is in early research stages (discovery/preclinical) and has not yet entered clinical trials. Its mechanism of action involves targeting TSHR, which suggests potential use in diseases related to thyroid function or other endocrine system disorders. The route of administration under investigation is parenteral.

Targets

TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on APB-R6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APB-R6.

Explore the full profile